Topical carmustine (BCNU) in the treatment of mycosis fungoides

Dermatol Ther. 2003;16(4):299-302. doi: 10.1111/j.1396-0296.2003.01641.x.

Abstract

The University of California, San Francisco (UCSF), experience with topical carmustine (BCNU) in the treatment of approximately 200 patients with mycosis fungoides (MF) is summarized. Topical BCNU is an effective treatment for patch- and early plaque-stage MF. Side-effects are usually not a major deterrent to continuation of therapy.

Publication types

  • Review

MeSH terms

  • Administration, Topical
  • Carmustine / administration & dosage*
  • Clinical Trials as Topic
  • Disease-Free Survival
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Mycosis Fungoides / diagnosis*
  • Mycosis Fungoides / drug therapy*
  • Mycosis Fungoides / mortality
  • Neoplasm Staging
  • Risk Assessment
  • Skin Neoplasms / diagnosis*
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / mortality
  • Survival Rate

Substances

  • Carmustine